Search Results
Bendamustine hydrochloride
Bendamustine hydrochloride is FDA approved to treat people who have:
- Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.
- Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Inotuzumab Ozogamicin
Inotuzumab ozogamicin is FDA approved for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older.
Acalabrutinib
Acalabrutinib is a kinase inhibitor indicated:
- In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).
- For the treatment of adult patients with MCL who have received at least one prior therapy.
- For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Meet the Researcher: Charlene Liao, PhD
Our “Meet the Researcher” series on The LLS Blog shares what our outstanding LLS-funded researchers are working on, the incredible impact they’re making in the fight against blood cancers, and what inspires their efforts to find better treatments and cures.
Improving Blood Cancer Survival Takes More than New Drug Discovery
In my years as a practicing hematologist-oncologist and now as chief medical officer of The Leukemia & Lymphoma Society (LLS), I’ve met many blood cancer patients who worry about how they’ll afford their treatment on top of day-to-day expenses like rent and groceries. LLS offers financial assistance for qualifying blood cancer patients and families
A Special Surprise for Pediatric Cancer Patient Counting Down the Days until Treatment Ends
"A Style for Every Smile” Campaign is Brightening the Faces of Pediatric Cancer Patients like 4-Year-Old Sasha Nationwide
At the tender age of four, Sasha has endured more than most of us will in a lifetime. In October 2017, at just two years old, she was diagnosed with acute lymphoblastic leukemia, a diagnosis no parent wants to hear.
"It sounds so stereotypical, but I just didn't believe it. I was completely in denial,” says Sasha’s mom, Randi.
How Celebrating My 18th Birthday in the Hospital Changed My Perspective
Marlee’s story of courage, inspiration and giving back.
My name is Marlee Pincus and I have cancer. I never in a million years thought I would say those words. Growing up, I never had any medical issues nor a significant family history of cancer. In high school I loved to run, advocate for human rights, and learn Spanish. However, my greatest focus was always on my academics. I graduated Salutatorian of my class and was eager to begin my freshman year at Cornell University.
Renewed focus on a national initiative to cure cancer
For more than 66 years The Leukemia & Lymphoma Society (LLS) has dedicated its energy and resources to finding cures for blood cancers, investing more than $1 billion over that time. Last night in his State of the Union address, President Obama appointed Vice President Joe Biden to take the lead in a “moon shot” mission to cure cancer. We at LLS agree the time is right.
“It’s personal for everybody,” the Vice President later said in a statement.
Is a Clinical Trial Right For You?
Because it can take up to 15 years for a new blood cancer drug to be studied and made available for doctors to prescribe, some patients opt for clinical trials as a way to gain early access to a promising treatment. Advancing new cancer therapies requires years of extensive clinical investigation, but clinical trials come with no guarantees. "A drug is allowed to enter the clinical trial phase based on scientific evidence including cell and animal studies, but it's still considered experimental and unproven.
#ASH18: Beating AML
Sunday marked a significant milestone for The Leukemia & Lymphoma Society (LLS) and the patients we help. Here at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, a conference attended by more than 30,000 scientists from around the world, we unveiled the first results from our groundbreaking precision medicine Beat AML Master Clinical Trial. To date, more than 356 patients have been screened for this trial.
NBA Rookie Honors Late Coach by Donating Car to LLS
Thanks to Karl-Anthony Towns, The Leukemia & Lymphoma Society (LLS) will be getting a brand new Kia!
The NBA awarded the 2015-16 Kia NBA Rookie of the Year Award to Karl-Anthony Towns of the Minnesota Timberwolves on May 16 by handing him keys to a brand new Sorento CUV.
Salesforce Doubles Million Dollar Impact on Cancer
They say, “Teamwork makes the dream work” and the 2016 Light The Night Salesforce team’s March to a Million initiative has proved this is true. As LLS’s longtime Light The Night partner, the team of more than 1,880 participants from across the U.S. went above and beyond this year to fight blood cancer. Not only did they meet their $1 million dollar fundraising goal, but Salesforce has generously offered to match it— bringing their total amount raised to more than $2 million for LLS’s goal to create a world without blood cancers!
#ASH16 (Blog 3): Teaming Up to Beat AML
This is the third in a series of blogs covering the 58th ASH Annual Meeting and Exposition (#ASH16).
Eight Years and Counting: "The Gray Zone"
If you want to get technical, I have cancer. At least I think I do. I was diagnosed eight years ago with chronic myeloid leukemia (CML) and while there are no longer any signs of disease in my bone marrow, this is a condition that never really goes away. The cancer-causing enzymes keep firing and my daily Gleevec pills continue pummeling them into submission. I like to think of myself as a cancer survivor, but dare I be so cocky? Not only do I not want to tempt fate, but it feels a bit like I’m staking claim to a territory I’m not fully entitled to.
Support at Your Fingertips: Try a Discussion Board
Having cancer can be a lonely experience, and it’s not always so easy to find others with a similar diagnosis. Even if you could, you might not always want to talk about everything face to face.
Sometimes an online discussion board is just what you need.
Another First: FDA Approves Car T-Immunotherapy for Treatment of Aggressive Form of Indolent Non-Hodgkin Lymphoma
The U.S. Food and Drug Administration (FDA) today approved the CAR T-cell treatment axicabtagene ciloleucel (Yescarta®) for patients with follicular lymphoma (FL) that has returned or worsened despite earlier treatment. FL is the most common slow-growing non-Hodgkin’s lymphoma and while the disease can generally be managed, reoccurrence is common.
Hydroxyurea
Hydroxyurea is FDA approved to treat people who have chronic myelocytic leukemia and some other blood cancers, including essential thrombocythemia and polycythemia vera. Hydroxyurea may cause temporary loss of hair in some people. After treatment has ended, normal hair growth should return, although the new hair may be a slightly different color or texture.
Methotrexate
Methotrexate is FDA approved, alone or with other drugs, to treat people who have acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to prevent ALL from spreading to the CNS. It is also FDA approved to treat people who have advanced non-Hodgkin lymphoma and advanced mycosis fungoides. It may also be used to treat people with other types of blood cancer.
Alemtuzumab
Alemtuzumab is FDA approved to treat people who have chronic lymphocytic leukemia (CLL).
Bosutinib
Bosutinib is FDA approved for the treatment of
- Adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly diagnosed or resistant or intolerant to prior therapy.
- Adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.
Decitabine and cedazuridine
Inqovi is FDA approved for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
Avapritinib
Ayvakit® is indicated for the treatment of